Literature DB >> 11938733

[Affect of insulin-like growth factor I and estradiol on the growth of uterine leiomyoma].

J Huang1, J Zou, B Xu, Y Zhang, X Chen, D Liu.   

Abstract

To study roles of insulun-like growth factor 1(IGF-I) and estradiol(E2) in the growth of leiomyoma. Protein expressions of IGF-I receptor(IGF-I-R), estrogen receptor(ER), and cell proliferation associated nuclear antigen(ki-67) were analysed by streptavidin-peroxide method in 40 cases. Serum level and local concentration of IGF-I were determined by immunoradiometric assay(IRMA) in 20 cases. Serum level of estradiol was determined by radioimmunoassay in 20 cases. Twenty normal fertile women were studied as control. Protein expressions of IGF-I-R and ER in uterine leiomyoma were significantly higher than in myometrium(P < 0.05); and local concentration of IGF-I positively correlated with ki-67 (r = 0.6513, P < 0.05); and expression of estrogen receptor. The serum levels of IGF-I and E2 had no significant difference between leiomyoma patients and normal women. IGF-I and E2 promote the growth of leiomyoma and IGF-I may act as a mediator of estrogen.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11938733

Source DB:  PubMed          Journal:  Hunan Yi Ke Da Xue Xue Bao        ISSN: 1000-5625


  2 in total

1.  Uterine leiomyomata in relation to insulin-like growth factor-I, insulin, and diabetes.

Authors:  Donna D Baird; Greg Travlos; Ralph Wilson; David B Dunson; Michael C Hill; Aimee A D'Aloisio; Stephanie J London; Joel M Schectman
Journal:  Epidemiology       Date:  2009-07       Impact factor: 4.822

2.  Estrogen Regulates MAPK-Related Genes through Genomic and Nongenomic Interactions between IGF-I Receptor Tyrosine Kinase and Estrogen Receptor-Alpha Signaling Pathways in Human Uterine Leiomyoma Cells.

Authors:  Linda Yu; Alicia B Moore; Lysandra Castro; Xiaohua Gao; Hoang-Long C Huynh; Michelle Klippel; Norris D Flagler; Yi Lu; Grace E Kissling; Darlene Dixon
Journal:  J Signal Transduct       Date:  2012-10-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.